Literature DB >> 25827832

The tumor virus landscape of AIDS-related lymphomas.

Aaron Arvey1, Akinyemi I Ojesina2, Chandra Sekhar Pedamallu2, Gianna Ballon3, Joonil Jung2, Fujiko Duke2, Lorenzo Leoncini4, Giulia De Falco4, Eric Bressman3, Wayne Tam3, Amy Chadburn5, Matthew Meyerson2, Ethel Cesarman3.   

Abstract

Immunodeficiency dramatically increases susceptibility to cancer as a result of reduced immune surveillance and enhanced opportunities for virus-mediated oncogenesis. Although AIDS-related lymphomas (ARLs) are frequently associated with known oncogenic viruses, many cases contain no known transforming virus. To discover novel transforming viruses, we profiled a set of ARL samples using whole transcriptome sequencing. We determined that Epstein-Barr virus (EBV) was the only virus detected in the tumor samples of this cohort, suggesting that if unidentified pathogens exist in this disease, they are present in <10% of cases or undetectable by our methods. To evaluate the role of EBV in ARL pathogenesis, we analyzed viral gene expression and found highly heterogeneous patterns of viral transcription across samples. We also found significant heterogeneity of viral antigen expression across a large cohort, with many patient samples presenting with restricted type I viral latency, indicating that EBV latency proteins are under increased immunosurveillance in the post-combined antiretroviral therapies era. Furthermore, EBV infection of lymphoma cells in HIV-positive individuals was associated with a distinct host gene expression program. These findings provide insight into the joint host-virus regulatory network of primary ARL tumor samples and expand our understanding of virus-associated oncogenesis. Our findings may also have therapeutic implications, as treatment may be personalized to target specific viral and virus-associated host processes that are only present in a subset of patients.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2015        PMID: 25827832      PMCID: PMC4432014          DOI: 10.1182/blood-2014-11-599951

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; A Telenti; M Egger
Journal:  BMJ       Date:  1999-07-03

2.  Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas.

Authors:  Dörte Bechtel; Julia Kurth; Claus Unkel; Ralf Küppers
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

3.  The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

Authors:  Antonella d'Arminio Monforte; Caroline A Sabin; Andrew Phillips; Jonathan Sterne; Margaret May; Amy Justice; Francois Dabis; Sophie Grabar; Bruno Ledergerber; John Gill; Peter Reiss; Matthias Egger
Journal:  Arch Intern Med       Date:  2005-02-28

4.  Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number.

Authors:  M J Kersten; J Van Gorp; S T Pals; F Boon; M H Van Oers
Journal:  Leuk Lymphoma       Date:  1998-08

5.  Clonal integration of a polyomavirus in human Merkel cell carcinoma.

Authors:  Huichen Feng; Masahiro Shuda; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

Review 6.  Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  J Natl Cancer Inst Monogr       Date:  1998

7.  Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones.

Authors:  Paul Young; Emma Anderton; Kostas Paschos; Rob White; Martin J Allday
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

8.  Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma.

Authors:  Dirk P Dittmer; Chelsey J Hilscher; Margaret L Gulley; Eric V Yang; Min Chen; Ronald Glaser
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

9.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.

Authors:  Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks
Journal:  Ann Intern Med       Date:  2008-05-20       Impact factor: 25.391

10.  The intersection of Epstein-Barr virus with the germinal center.

Authors:  Jill E Roughan; David A Thorley-Lawson
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

View more
  25 in total

Review 1.  Extrafollicular activities: perspectives on HIV infection, germinal center-independent maturation pathways, and KSHV-mediated lymphoproliferation.

Authors:  Jennifer Totonchy
Journal:  Curr Opin Virol       Date:  2017-08-03       Impact factor: 7.090

2.  Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

Authors:  Álvaro H Borges; Jacqueline Neuhaus; Abdel G Babiker; Keith Henry; Mamta K Jain; Adrian Palfreeman; Peter Mugyenyi; Pere Domingo; Christian Hoffmann; Tim R H Read; Sanjay Pujari; Michael Meulbroek; Margaret Johnson; Timothy Wilkin; Ronald Mitsuyasu
Journal:  Clin Infect Dis       Date:  2016-09-08       Impact factor: 9.079

Review 3.  Serious Non-AIDS Conditions in HIV: Benefit of Early ART.

Authors:  Jens D Lundgren; Alvaro H Borges; James D Neaton
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

4.  Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences.

Authors:  Yasin Kaymaz; Cliff I Oduor; Hongbo Yu; Juliana A Otieno; John Michael Ong'echa; Ann M Moormann; Jeffrey A Bailey
Journal:  Mol Cancer Res       Date:  2017-05       Impact factor: 5.852

5.  An Endotracheal Plasmablastic Lymphoma.

Authors:  Eva M T Bots; Johan Opperman; Fatima Bassa; Coenraad F N Koegelenberg
Journal:  Respiration       Date:  2019-10-21       Impact factor: 3.580

6.  Novel insights into the early histopathogenesis of immunodeficiency-associated Burkitt lymphoma: a case report of Burkitt microlymphoma arising within HIV lymphadenitis.

Authors:  David Park; Neval Ozkaya; Aparna Hariharan
Journal:  Histopathology       Date:  2016-05-20       Impact factor: 5.087

Review 7.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

8.  Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.

Authors:  An T Phan; Samantha G Fernandez; Jessica J Somberg; Kristin M Keck; Jj L Miranda
Journal:  Biochem Biophys Res Commun       Date:  2016-04-16       Impact factor: 3.575

9.  Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.

Authors:  Tanner Dalton; Ekaterina Doubrovina; Dmitry Pankov; Raymond Reynolds; Hanna Scholze; Annamalai Selvakumar; Teresa Vizconde; Bhumesh Savalia; Vadim Dyomin; Christoph Weigel; Christopher C Oakes; Alicia Alonso; Olivier Elemento; Heng Pan; Jude M Phillip; Richard J O'Reilly; Benjamin E Gewurz; Ethel Cesarman; Lisa Giulino-Roth
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

Review 10.  A lymphomagenic role for HIV beyond immune suppression?

Authors:  Riccardo Dolcetti; Annunziata Gloghini; Arnaldo Caruso; Antonino Carbone
Journal:  Blood       Date:  2016-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.